Recursion Pharmaceuticals Stock Beta
| RXRX Stock | USD 7.01 0.34 5.10% |
Recursion Pharmaceuticals fundamentals help investors to digest information that contributes to Recursion Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Recursion Stock. The fundamental analysis module provides a way to measure Recursion Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Recursion Pharmaceuticals stock.
Recursion | Beta |
Recursion Pharmaceuticals Company Beta Analysis
Recursion Pharmaceuticals' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Recursion Pharmaceuticals Beta | 0.8 |
Most of Recursion Pharmaceuticals' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Recursion Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Recursion Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Recursion Pharmaceuticals is extremely important. It helps to project a fair market value of Recursion Stock properly, considering its historical fundamentals such as Beta. Since Recursion Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Recursion Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Recursion Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Recursion Pharmaceuticals has a Beta of 0.797. This is 7.33% lower than that of the Biotechnology sector and 42.66% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Recursion Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Recursion Pharmaceuticals' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Recursion Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Recursion Pharmaceuticals by comparing valuation metrics of similar companies.Recursion Pharmaceuticals is currently under evaluation in beta category among its peers.
Recursion Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Recursion Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Recursion Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Recursion Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Recursion Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Recursion Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Recursion Pharmaceuticals' value.| Shares | Nvidia Corp | 2024-06-30 | 7.7 M | Data Collective Iv Gp, Llc | 2024-06-30 | 5.9 M | Geode Capital Management, Llc | 2024-06-30 | 4.8 M | Dcvc Opportunity Fund Ii Gp, Llc | 2024-06-30 | 4 M | Exor Investments (uk) Llp | 2024-06-30 | 3.7 M | Laurion Capital Management Lp | 2024-06-30 | 2.9 M | Ubs Asset Mgmt Americas Inc | 2024-06-30 | 2.1 M | Norges Bank | 2024-06-30 | 1.9 M | Credit Suisse First Boston (csfb) | 2024-03-31 | 1.9 M | Ark Investment Management Llc | 2024-06-30 | 28.1 M | Baillie Gifford & Co Limited. | 2024-06-30 | 26.6 M |
As returns on the market increase, Recursion Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Recursion Pharmaceuticals is expected to be smaller as well.
Recursion Fundamentals
| Return On Equity | -0.71 | ||||
| Return On Asset | -0.34 | ||||
| Operating Margin | (6.97) % | ||||
| Current Valuation | 1.56 B | ||||
| Shares Outstanding | 284.19 M | ||||
| Shares Owned By Insiders | 4.44 % | ||||
| Shares Owned By Institutions | 88.59 % | ||||
| Number Of Shares Shorted | 62.58 M | ||||
| Price To Book | 3.33 X | ||||
| Price To Sales | 41.17 X | ||||
| Revenue | 44.58 M | ||||
| Gross Profit | (164.13 M) | ||||
| EBITDA | (317.6 M) | ||||
| Net Income | (328.07 M) | ||||
| Cash And Equivalents | 515.44 M | ||||
| Cash Per Share | 2.98 X | ||||
| Total Debt | 50.67 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 5.65 X | ||||
| Book Value Per Share | 2.08 X | ||||
| Cash Flow From Operations | (287.78 M) | ||||
| Short Ratio | 12.15 X | ||||
| Earnings Per Share | (1.74) X | ||||
| Price To Earnings To Growth | (0.60) X | ||||
| Target Price | 10.14 | ||||
| Number Of Employees | 500 | ||||
| Beta | 0.8 | ||||
| Market Capitalization | 2.04 B | ||||
| Total Asset | 653.7 M | ||||
| Retained Earnings | (967.62 M) | ||||
| Working Capital | 344.97 M | ||||
| Net Asset | 653.7 M |
About Recursion Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Recursion Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Recursion Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Recursion Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| AVAV | AeroVironment | |
| ELVN | Enliven Therapeutics | |
| NFLX | Netflix |
Additional Tools for Recursion Stock Analysis
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.